Drug Profile


Alternative Names: Akatinol; Axura; Ebixa; Extended-release memantine capsules - Allergan; Memantine hydrochloride; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Medical Center Corporation
  • Developer Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Dementia
  • Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X syndrome; Glaucoma; Neuropathic pain; Vascular dementia

Most Recent Events

  • 12 Sep 2017 Daiichi Sankyo completes a clinical trial for Alzheimer's disease in Japan (UMIN000016420)
  • 31 May 2017 Daiichi Sankyo completes a phase III trial for Alzheimer's disease in Japan (JapicCTI-163209)
  • 26 Apr 2017 Daiichi Sankyo and Katayama Medical Clinic terminates a clinical trial for Alzheimer's disease (Combination therapy) in Japan (UMIN000021140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top